Дурацеф

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Дурацеф

Quick Facts

Property Description
Active ingredient Cefadroxil
Form Capsules, Tablets, Oral Suspension
Pharmacological class beta-Lactam antibiotic
General purpose Anti-infective agent (Bactericidal)
Origin Semi-synthetic

Дурацеф: Identity and Core Classification

Дурацеф (Duracef) is the trade name for the semi-synthetic, single-agent therapeutic product whose active component is the antibiotic Cefadroxil. Cefadroxil is chemically classified as a beta-Lactam antibiotic, belonging specifically to the first-generation cephalosporin group. This classification defines the substance's core activity and stability. The medicine belongs to a family of drugs recognized for destroying bacteria. It is an oral prescription medicine, clinically recognized for its reliable action against specific susceptible organisms.

Cefadroxil: Chemical Nature and Pharmaceutical Form

The active ingredient, Cefadroxil, is typically formulated as the stable Cefadroxil Monohydrate salt for efficient oral delivery and systemic distribution. Cefadroxil is manufactured into several high-level dosage forms, including solid capsules and tablets, as well as a powder for oral suspension. The suspension formulation often includes specific excipients to improve palatability, a key consideration for pediatric patients requiring accurate systemic dosing.

General Purpose of the First-Generation Cephalosporin

The primary purpose of Cefadroxil is to provide a decisive bactericidal effect. This means the drug is designed to actively kill susceptible infection-causing bacteria, defining its role as an effective systemic anti-infective solution. Cefadroxil achieves this by targeting and destroying the vital, protective cell wall of the microorganism, preventing its survival and replication.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Дурацеф?

Official Adverse Reactions and Safety Profile

The safety profile of Дурацеф (Cefadroxil) is officially classified by frequency and the body system affected, based on regulatory standards from government agencies. The adverse reactions are primarily categorized as affecting the Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Infections and Infestations System Organ Classes.

Frequency Classification Examples of Reactions
Common (ge 1/100 to <1/10) Nausea, diarrhea, vomiting, abdominal pain, pruritus (itching), rash.
Uncommon (ge 1/1,000 to <1/100) Vaginal mycoses (thrush).
Rare (ge 1/10,000 to <1/1,000) Serum sickness-like reactions, agranulocytosis, interstitial nephritis.
Very Rare (<1/10,000) Anaphylactic shock.

Serious adverse reactions, though rare, include life-threatening Anaphylactic shock and severe gastrointestinal issues like Pseudomembranous colitis. Rare dermatological events such as Stevens-Johnson syndrome have also been reported.

Safety constraints documented in regulatory labels highlight specific considerations. Due to its classification, Cefadroxil has a documented risk of cross-sensitivity with penicillins. Caution is explicitly noted for individuals with a history of gastrointestinal disease, particularly colitis. Furthermore, patients with markedly impaired renal function require specific attention, as the drug is mainly excreted by the kidneys. Prolonged use is associated with the potential overgrowth of non-susceptible organisms (superinfection) and rare hematologic events.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes the typical presentation of an overdose with Cefadroxil (Дурацеф) as involving acute gastrointestinal symptoms, predominantly nausea, vomiting, and diarrhea. However, exposure to massive quantities or administration in the presence of impaired renal function may lead to more serious manifestations. These include signs of central nervous system (CNS) excitation, such as the potential for seizures and convulsions, as the regulator-documented risk of CNS toxicity is increased with higher drug accumulation.

The mandatory regulatory instruction for any suspected overexposure is to seek immediate medical attention. Furthermore, official prescribing information explicitly states that no specific antidote is known for Cefadroxil overdosage.

Management of overdose is officially defined as symptomatic and supportive treatment. While interventions like gastric decontamination may be considered, severe intoxication management relies on regulatory procedures. Cefadroxil is documented to be significantly removed by hemodialysis, which is an officially recognized method that may be employed to accelerate the drug's elimination from the body in severe cases.

Therapeutic Uses of Дурацеф

What Дурацеф Treats: Main Uses and Benefits

Дурацеф (Cefadroxil) is applied across therapeutic domains where additional symptomatic support is needed. It is relevant in contexts involving heightened systemic burden to help ease the overall symptom burden. The medication is considered relevant in situations with significant discomfort, and its use is indicated for conditions such as skin and soft tissue infections, throat and tonsil infections, and certain urinary tract episodes.

The medicine supports the patient during difficult episodes by easing distress related to common illnesses. The medication is considered relevant in situations with significant discomfort.

The drug is commonly used to help with symptoms related to inflammatory or irritative states. For example, in skin infections, it helps address symptoms related to physical discomfort, and for throat infections, it assists in managing fever and symptoms that interfere with daily functioning.

Quick Fact: Support for Symptoms Related to Irritative States Дурацеф is commonly used to help with symptoms related to inflammatory or irritative states across multiple therapeutic areas, assisting with the management of symptoms related to physical discomfort.

Eligibility and Restrictions for Use

The official eligibility for Дурацеф (Cefadroxil) is strictly defined by regulatory documents, specifying populations that are prohibited from use and those who require conditional administration.

Eligibility scope

Classification Official Regulatory Status
Populations for whom use is allowed Adults and adolescents without stated contraindications. Pediatric patients are generally eligible, with age-specific formulation rules for younger children.
Populations for whom use is contraindicated Patients with known hypersensitivity (allergy) to Cefadroxil or the cephalosporin group of antibiotics. Caution is necessary for patients with a history of penicillin allergy due to documented cross-sensitivity among beta-Lactam antibiotics.

Condition-specific eligibility rules

  • Renal Impairment: Use is restricted for patients with markedly impaired renal function (creatinine clearance less than 50 mL/min/1.73 M^2), which necessitates a special clinical evaluation and adjustment of the dosing interval.
  • Gastrointestinal History: Use requires caution in individuals with a history of gastrointestinal disease, particularly colitis.

Age and Reproductive Eligibility Status

  • Infants: Safety and effectiveness for all indications are not established in infants less than 1 year of age.
  • Older Adults: Generally eligible, but use should be cautious due to the higher likelihood of decreased renal function.
  • Pregnancy: Classified as Pregnancy Category B. Use is only permissible if clearly needed.
  • Lactation: Caution is recommended when administered to a nursing mother, as Cefadroxil is distributed into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Дурацеф (Cefadroxil) based on pharmacokinetic and pharmacodynamic outcomes, establishing specific usage constraints.

Documented Drug-Drug Interactions

Interacting Product Category Regulatory Outcome and Restriction
Bacteriostatic Antibiotics (e.g., Tetracycline, Erythromycin) Antagonism is possible; co-administration is officially advised against due to the risk of reduced antibacterial efficacy.
Nephrotoxic Agents (e.g., Aminoglycosides) and High-Dose Loop Diuretics Combination should be avoided to prevent the potentiation of nephrotoxic effects.
Probenecid Reduces the renal elimination of Cefadroxil, resulting in increased plasma concentrations of the drug (Exposure Modification).

Other Documented Interactions

Cefadroxil may reduce the immune response to certain live bacterial vaccines (e.g., BCG, Typhoid Live). The regulatory label also notes that Cefadroxil does not interfere with food absorption. However, it can cause falsely elevated values in urinary glucose reduction tests and may lead to a positive direct Coombs' test.

Mechanism of Action

Targeted Inhibition of Bacterial Cell Wall Assembly

The core mechanism of Cefadroxil involves the inactivation of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for the construction of the protective cell wall. The drug acts as a covalent inhibitor, binding permanently to the active site of these PBPs to prevent the necessary transpeptidation (cross-linking) of the peptidoglycan structure. This molecular action defines the onset of the drug's effect, focusing exclusively on the microbial target without affecting host cells.

Cascade Leading to Osmotic Lysis

Inhibiting the cell wall cross-linking initiates a rapid cascade that leads to the physiological failure of the bacterium. The resulting structurally fragile cell wall fails to withstand the high osmotic pressure exerted by the internal contents of the bacterium. This physiological failure leads directly to cell rupture and death (lysis), resulting in the reduction of the microbial population, a bactericidal effect that actively kills the cell rather than halting its growth.

Mechanism Constraints and Resistance Pathways

The efficacy of this bactericidal mechanism is subject to specific constraints, notably microbial resistance. Bacteria that produce β-Lactamase enzymes can hydrolyze and inactivate the Cefadroxil molecule before it reaches the PBP target, rendering the mechanism inert. Furthermore, the drug achieves poor concentration behind the blood-brain barrier, limiting the action of this mechanism in the central nervous system.

Dosage and Administration Information

How to Use Дурацеф (Cefadroxil) — Administration Guidelines

This section describes the standardized approach to administering Дурацеф (Cefadroxil), focusing on instructions for use.


Administration Protocol

Instruction Detail
Route of Administration The drug is intended for oral intake as capsules, tablets, or liquid suspension.
Dosing Schedule Standard adult regimens range from 1 gram to 2 grams per day.
Timing in relation to meals Administration may occur with or without food; instructions advise taking it with food to potentially minimize gastrointestinal discomfort.
Duration of Therapy Treatment must continue for a minimum of 10 days for infections caused by Group A beta-hemolytic streptococci.

Frequency and Special Conditions

Frequency Pattern: Dosing follows a once-daily (q.d.) or twice-daily (b.i.d.) schedule. The once-daily regimen often applies to uncomplicated lower urinary tract infections and pharyngitis, while twice-daily dosing is used for certain other indications and as an alternative approach.

Population-Specific Adjustment: Dosage must be adjusted in adult patients with impaired renal function, specifically when creatinine clearance is le 50 mL/min. This modification involves administering a 500 mg maintenance dose at extended intervals (e.g., 12, 24, or 36 hours) following an initial 1 g dose.

Procedural Constraints: The oral suspension form requires reconstitution and must be shaken well before each use. If a dose is missed, it should be taken as soon as remembered, but doubling doses to compensate is not permitted.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Дурацеф (Cefadroxil)


Evidence for Use in Skin and Soft Tissue Infections

Research for this indication primarily consists of short-term, comparative Randomized Controlled Trials (RCTs) and open-label clinical studies. Researchers examined outcomes related to physical discomfort by measuring the measured clinical endpoints (visual resolution or improvement in the infection) and the bacteriological eradication rate (the measured elimination of susceptible organisms) in adults and children. Studies reported measurements consistent with the defined short-term eradication and clinical endpoints in the observed populations. The trials often examined Cefadroxil against other agents, including older first-generation antibiotics. The research examined outcomes where the applicability to current microbial resistance patterns remains a subject of investigation.


Evidence for Use in Throat and Tonsil Infections (Pharyngitis/Tonsillitis)

For infections characterized by fluctuating or episodic manifestations in the throat and tonsils, research was primarily explored through short-term clinical trials. These studies were evaluated in adults and children with laboratory-confirmed Streptococcus pyogenes infections. Studies monitored outcomes related to systemic or functional imbalance by measuring the bacteriological eradication rate and the measured clinical endpoints after the standard course of therapy. Studies report how symptoms evolved in the observed populations, and findings indicate patterns related to the elimination of the target organism and symptom resolution.


Evidence for Use in Uncomplicated Urinary Tract Infections

The evidence for uncomplicated UTIs comes from short-term and intermediate-duration clinical trials. Research examined populations of adults presenting with acute UTIs by measuring bacteriological eradication (achieving sterile urine) and measured symptom-based outcomes (resolution of symptoms linked to the infection). Trials reported measurements of these endpoints in the studied populations, with follow-up periods extending a few weeks after treatment. Findings reflect the specific characteristics of the populations studied. Research focusing on long-term infection prevention or recurrence patterns is not a central focus of the core clinical trials.


What is Still Uncertain About Дурацеф’s Evidence Base

Evidence highlights what is known—and what is still uncertain—about the research for this treatment. A key research limitation is that many trials compared the treatment against older agents, and comprehensive comparative data against other specific cephalosporins or standard-of-care agents may be lacking. Furthermore, for conditions like bone and joint infections, the research base includes small case reports rather than large randomized controlled trials. Finally, long-term effects related to durability and outcomes related to the avoidance of specific long-term complications (like rheumatic fever) are not fully established by the current research.

Frequently Asked Questions (FAQ)

Common questions about Дурацеф (FAQ)

Q: What type of infections is Дурацеф most commonly used to treat?

According to official product information, Дурацеф (Cefadroxil) is prescribed for treating infections caused by susceptible bacteria. These typically include specific kinds of skin and skin structure infections, infections of the throat and tonsils (such as pharyngitis/tonsillitis caused by Streptococcus pyogenes), and certain uncomplicated urinary tract infections (UTIs).

Q: Why is it important to finish the whole course of Дурацеф even if I feel better?

Official regulatory information emphasizes that the full prescribed course of antibiotics should be completed. Stopping treatment early or skipping doses may lead to an incomplete treatment of the infection. This failure to fully eradicate the bacteria could also contribute to the development of antibiotic resistance.

Q: How quickly does Дурацеф usually start to show an effect?

Cefadroxil is described as being rapidly and completely absorbed after it is taken by mouth. Regulatory information indicates that effects or improvements are often observed by patients during the first few days of treatment.

Q: Is Дурацеф considered a broad-spectrum antibiotic?

Дурацеф belongs to the first-generation cephalosporin class of antibiotics. Its activity is targeted toward specific susceptible organisms, including certain Gram-positive bacteria and a limited range of Gram-negative bacteria.

Q: Is it true that Дурацеф will not work for viral infections like the common cold?

Yes, this medicine is designed to work by killing susceptible bacteria (it is bactericidal). The drug is therefore not intended for use in treating infections that are caused by viruses, such as the common cold or the flu.

Q: How is Дурацеф different from Amoxicillin or other common antibiotics?

Дурацеф (Cefadroxil) is chemically classified as a cephalosporin, which is a distinct family of antibiotics from the penicillin class (which includes Amoxicillin). Official safety information highlights a documented risk of cross-sensitivity between these two beta-Lactam antibiotic classes.

Q: Does Дурацеф interact with commonly used over-the-counter painkillers like Ibuprofen?

Professional interaction references, based on regulatory data, often indicate no major interaction is expected between Cefadroxil and over-the-counter painkillers like Ibuprofen. However, official advice notes caution when taking any medication, particularly those that affect the kidneys, and review of all potential interactions by a health professional is advised.

Q: Are there any known interactions between Дурацеф and birth control pills?

Some official professional guidelines suggest that antibiotics like Cefadroxil may potentially reduce the effectiveness of certain estrogen-containing oral contraceptives. Discussion of this potential interaction with a healthcare provider is noted for patients using these contraceptives.

Q: Is it recommended to avoid alcohol while taking Дурацеф?

The official regulatory labeling for Cefadroxil does not list a specific drug-alcohol interaction that prohibits consumption. However, it is commonly noted that patients may wish to discuss the use of alcohol with a healthcare professional while on a course of treatment.

Q: Can taking Дурацеф cause dizziness or lightheadedness?

Yes, regulatory documents list dizziness and headache as possible nervous system disorders. Official safety information classifies these side effects as rare or of unknown frequency.

Q: What is the risk of developing C. difficile-associated diarrhea with Дурацеф?

The official labeling states that Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including Cefadroxil. This condition can vary in severity from mild diarrhea to a severe and potentially life-threatening gastrointestinal issue known as colitis.

Q: What types of bacteria is Дурацеф generally active against?

According to the official Summary of Product Characteristics, Cefadroxil is active against certain susceptible bacterial species. These include Gram-positive bacteria such as certain Streptococci and Staphylococci, and some common Gram-negative organisms like E. coli and Proteus mirabilis.

Q: Is it true that Дурацеф is mostly excreted unchanged in the urine?

Yes. Pharmacokinetic data included in regulatory documents indicate that the majority of the administered dose, typically over 90%, is excreted as the unchanged drug through the urine within 24 hours of administration.

Q: Does taking Дурацеф affect the body's natural gut bacteria?

Antibiotics, including Cefadroxil, may affect the normal bacterial flora in the body. This alteration can affect the normal flora of the colon, sometimes leading to issues such as diarrhea and the potential overgrowth of non-susceptible organisms (known as superinfection).

Q: Can Дурацеф be used for an infection in the ear (otitis media)?

Cefadroxil is primarily indicated for approved uses such as throat, skin, and urinary tract infections. While professional references may mention its use for some upper respiratory tract infections, it is not listed as a primary, officially labeled treatment for acute otitis media in core regulatory documents.

Q: Is there a known link between Дурацеф and joint pain?

Yes, official safety documents list joint pain, known medically as arthralgia, as a reported adverse reaction. This reaction is generally listed in the rare category associated with Cefadroxil use.

How should Дурацеф be stored and disposed of?

Storage and Disposal Requirements for Duracef (Cefadroxil Monohydrate)

Solid forms of Duracef (capsules, tablets) must be stored at controlled room temperature, generally 20 C to 25 C (68 F to 77 F). The solid medicine must be kept in a tight container, protected from excess heat and moisture.

The reconstituted liquid suspension has different requirements. It must be stored in the refrigerator and maintained in a tightly closed container, but it must not be frozen. Any unused portion of the refrigerated suspension must be discarded after 14 days from the date of preparation.

All forms of this medication must be stored out of the sight and reach of children. Unused, expired, or no longer needed medicine should not be saved and should be disposed of according to official regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Дурацеф found in:

A-Z Index: